{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:24:57Z","timestamp":1770499497767,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ejca.2004.01.019","type":"journal-article","created":{"date-parts":[[2004,3,17]],"date-time":"2004-03-17T10:36:05Z","timestamp":1079519765000},"page":"1159-1169","source":"Crossref","is-referenced-by-count":41,"title":["A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II\/III multiple myeloma"],"prefix":"10.1016","volume":"40","author":[{"given":"M.","family":"van Agthoven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Segeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Buijt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"van der Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.M.","family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2004.01.019_BIB1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2004.01.019_BIB2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"The treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejca.2004.01.019_BIB4","first-page":"318","article-title":"Chemotherapy of previously untreated multiple myeloma patients","volume":"13","author":"Sporn","year":"1986","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0277-5379(89)90001-1","article-title":"Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?","volume":"25","author":"Bergsagel","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB6","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2141.1994.tb06745.x","article-title":"Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group","volume":"87","author":"Tsuchiya","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2004.01.019_BIB8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","article-title":"Multiple myeloma treated with high dose intravenous melphalan","volume":"66","author":"Selby","year":"1987","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejca.2004.01.019_BIB10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejca.2004.01.019_BIB11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2004.01.019_BIB12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1046\/j.1365-2141.2001.02854.x","article-title":"Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma","volume":"113","author":"Sampson","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB13","series-title":"Methods for the economic evaluation of health care programs","author":"Drummond","year":"1997"},{"key":"10.1016\/j.ejca.2004.01.019_BIB14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2004.01.019_BIB15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1999.01279.x","article-title":"Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma","volume":"105","author":"Segeren","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.1996.00306.x","article-title":"Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma","volume":"92","author":"Lokhorst","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB17","series-title":"Cost Accounting: A Managerial Emphasis","author":"Horngren","year":"2000"},{"key":"10.1016\/j.ejca.2004.01.019_BIB18","series-title":"Manual for Costing Research (in Dutch)","author":"Oostenbrink","year":"2000"},{"key":"10.1016\/j.ejca.2004.01.019_BIB19","series-title":"Cost-effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.ejca.2004.01.019_BIB20","series-title":"Pharmacotherapeutical Compass 2000\/2001 (in Dutch)","author":"van der Kuy","year":"2000"},{"key":"10.1016\/j.ejca.2004.01.019_BIB21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00019053-200321040-00004","article-title":"Unit costs of inpatient hospital days","volume":"21","author":"Oostenbrink","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejca.2004.01.019_BIB22","series-title":"Intensive Therapy in Multiple Myeloma","author":"Segeren","year":"2002"},{"key":"10.1016\/j.ejca.2004.01.019_BIB23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.ejca.2004.01.019_BIB24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med. Care"},{"key":"10.1016\/j.ejca.2004.01.019_BIB25","series-title":"Supplemental Study of the Scope of the Drug Reimbursement System","article-title":"Testing the iMTA-model. Identification of disorders with minimal burden of disease, and testing of the efficiency test corrected for burden of disease","author":"Stolk","year":"2002"},{"key":"10.1016\/j.ejca.2004.01.019_BIB26","doi-asserted-by":"crossref","unstructured":"Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. Canberra, 1999.","DOI":"10.1071\/AH000216"},{"key":"10.1016\/j.ejca.2004.01.019_BIB27","series-title":"Guidelines for Pharmacoeconomic Research (in Dutch)","author":"Riteco","year":"1999"},{"key":"10.1016\/j.ejca.2004.01.019_BIB28","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1017\/S0266462399153157","article-title":"Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals","volume":"15","author":"Severens","year":"1999","journal-title":"Int. J. Technol. Assess Health Care"},{"key":"10.1016\/j.ejca.2004.01.019_BIB29","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials","volume":"19","author":"Barber","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejca.2004.01.019_BIB30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O","article-title":"Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane","volume":"7","author":"Briggs","year":"1998","journal-title":"Health Econ."},{"key":"10.1016\/j.ejca.2004.01.019_BIB31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1447::AID-SIM267>3.0.CO;2-V","article-title":"Estimating confidence intervals for cost-effectiveness ratios","volume":"15","author":"Chaudhary","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejca.2004.01.019_BIB32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1008252227512","article-title":"High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma","volume":"8","author":"Goldschmidt","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2141.2000.01979.x","article-title":"Conditioning regimens in autologous stem cell transplantation for multiple myeloma","volume":"109","author":"Lahuerta","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB34","first-page":"1175","article-title":"An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma","volume":"18","author":"Duncan","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2004.01.019_BIB35","first-page":"79","article-title":"Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma","volume":"16","author":"Ager","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2004.01.019_BIB36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1700900","article-title":"Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma","volume":"20","author":"Jagannath","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2004.01.019_BIB37","first-page":"1192","article-title":"Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma","volume":"87","author":"Morabito","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2004.01.019_BIB38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00019053-200119080-00006","article-title":"Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma","volume":"19","author":"Coyte","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejca.2004.01.019_BIB39","first-page":"19","article-title":"Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma","volume":"16","author":"Henon","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2004.01.019_BIB40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta2080","article-title":"Bone marrow and peripheral blood stem cell transplantation for malignancy","volume":"2","author":"Johnson","year":"1998","journal-title":"Health Technol. Assess"},{"key":"10.1016\/j.ejca.2004.01.019_BIB41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1034\/j.1600-0609.2001.066005328.x","article-title":"Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma","volume":"66","author":"Gulbrandsen","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejca.2004.01.019_BIB42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-199916040-00002","article-title":"Therapeutic options in the treatment of multiple myeloma","volume":"16","author":"Wisloff","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejca.2004.01.019_BIB43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","article-title":"The role of autologous transplantation in patients with multiple myeloma aged 65 years and over","volume":"25","author":"Sirohi","year":"2000","journal-title":"Bone Marrow Transplant"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904001285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904001285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T17:12:31Z","timestamp":1585674751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0959804904001285"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.01.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}